A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression

Psychopharmacology Bulletin

Volumn 33, Issue 4, 1997, Pages 671-676

  Entsuah, Richard ^b   Chitra, Rohini ^a  

^a Wyeth Ayerst Laboratories   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

Benefit; Depression; Extended release; Risk; Venlafaxine

Indexed keywords

PLACEBO; VENLAFAXINE;

ADULT; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SOMNOLENCE; STATISTICAL ANALYSIS; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; VERTIGO;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DIZZINESS; HUMANS; NAUSEA; SEROTONIN UPTAKE INHIBITORS; STATISTICS;

EID: 0031405572     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3d ed., revísed. Washington, DC: The Association, 1987.
2. Andrews, JR. Benefit, risk, and optimization by ROC analysis in cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Physics 11:1557-1562, 1985.
3. Benkert, O; Gründer, G; Wetzel, H; and Hackett, D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J. Psychiatr. Res. 30:441-451, 1996.
4. Chang, RW, and Fineberg, HV. Risk-benefit considerations in the management of polymyalgia rheumatica. Med. Decis. Making 3:459-475, 1983.
5. Chuang-Stein, C; Mohberg, NR; and Sinkula, MS. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat. Med. 10:1349-1359, 1991.
6. Clerc, GE; Ruimy, P; and Verdeau-Pailles, J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int. Clin. Psychopharmacol. 9:138-143, 1994.
7. Cunningham, LA, for the Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann. Clin. Psychiatry 9:157-164, 1997.
8. Cunningham, LA; Borison, RL; Carman, JS; Chouinard, G; Crowder, JE; Diamond, BI; Fischer, DE; and Hearst, E. A comparison of venlafaxine, trazodone, and placebo in major depression. J. Clin. Psychopharmacol. 14:99-106, 1994.
9. Dierick, M; Ravizza, L; Realini, R; and Martin, A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog. Neuropsychopharmacol. Biol. Psychiatry 20:57-71, 1996.
10. Emerson, JD, and Tritchler, D. The three-decision problem in medical decision making. Stat. Med. 6:101-112, 1987.
11. Entsuah, R; Upton, GV; and Rudolph, R. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: A meta-analysis. Hum. Psychopharmacol. 10:195-200, 1995
12. Guelfi, JD; White, C; Hackett, D; Guichoux, JY; and Magni, G. Effectiveness of venlafaxine in patients hospitalized with major depression and melancholia. J. Clin. Psychiatry 56:450-458, 1995.
13. Guy, W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976.
14. Hamilton, MA. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56-62, 1960.
15. Khan, A; Rudolph, R; Baumel, B; Ferguson, J; Ryan, P; and Shrivastava, R. Venlafaxine in depressed geriatric outpatients: An open-label clinical study. Psychopharmacol. Bull. 31:753-758, 1995.
16. Lane, D, and Hutchinson, TA. The notion of "acceptable risk": The role of utility in drug management. J. Chronic Dis. 40:621-625, 1987.
17. Lecrubier, Y; Bourin, M; Moon, CAL; Schifano, F; Blanchard, C; Danjou, P; and Hackett, D. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr. Scand. 95:485-493, 1997.
18. Machina, MJ. Decision-making in the presence of risk. Science 236:537-543, 1987.
19. Montgomery, SA, and Åsberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134:382-389, 1979.
20. Muth, EA; Haskins, JT; Moyer, JA; Husbands, GE; Nielsen, ST; and Sigg, SB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35:4493-4497, 1986.
21. Payne, JG, and Loken, MK. A survey of the benefits and risk in the practice of radiology. CRC Crit. Rev. Clin. Radiol. Nucl. Med. 6:425-439, 1975.
22. Rey, JM; Morris-Yates, A; and Stanislaw, H. Measuring the accuracy of diagnostic tests using receiver operating characteristics (ROC) analysis. Int. J. Methods Psychiatr. Res. 2:39-50, 1992.
23. Schweizer, E; Feighner, J; Mandos, L; and Rickels, K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J. Clin. Psychiatry 55:104-108, 1994.
24. Shrivastava, R; Cohn, C; Crowder, J; Davidson, J; Dunner, D; Feighner, J; Kiev, A; and Patrick, R. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J. Clin. Psychopharmacol. 14:322-329, 1994.
25. Tallarida, RJ; Murrah, RB; and Eiben, C. A scale for assessing the severity of diseases and adverse drug reactions, application to drug benefit and risk. Clin. Pharmacol. Ther. 25:381-390, 1979.
26. Tylee, A; Beaumont, G; Bowden, M; and Reynolds, A. A double-blind, randomized, 12-week study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Prim. Care Psychiatry 3:51-58, 1997.
27. Weinstein, MC, and Fineberg, HV. Clinical Decision Analysis. Philadelphia, PA: Saunders, 1980.